Acadia falls as rare disease therapy fails late-stage trial

Acadia Pharmaceuticals

24/09/2025 12:51

** Shares of drugmaker Acadia Pharmaceuticals ACAD.O fall 11% to $21 premarket

** Co says its experimental therapy to treat a rare metabolic condition failed to meet main goal in late-stage study

** ACAD was testing treatment ACP-101 to treat hyperphagia, or feelings of intense and persistent hunger, in patients with genetic disorder called Prader-Willi syndrome

** Says co does not plan to investigate therapy any further

** Shares of rival drugmaker Soleno Therapeutics SLNO.O rose 13.5% premarket

** Up to last close, ACAD up 28.6% and SLNO up 26.5% YTD

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))